Biogen Inc. last reported quarterly results on Oct 28, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $2.8 billion (+10.6% year over year) and diluted EPS of -$0.14. It usually reports 1–28 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 13, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Jan 14, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 1–28 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 28, 2026
28 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
2,804
+10.6%
|
-21
-104.4%
|
-0.14
-104.4%
|
|
Jul 1, 2026
1 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
2,736
+3.4%
|
98
-84.6%
|
0.66
-84.8%
|
|
Apr 6, 2026
6 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
2,478
+1.9%
|
320
+32.8%
|
2.15
+31.1%
|
|
Jan 14, 2026
14 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
2,279
-7.1%
|
-49
-118.3%
|
-0.33
-118.0%
|
|
Oct 14, 2025
14 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
2,535
+2.8%
|
466
+20.1%
|
3.17
+19.2%
|
|
Jul 7, 2025
7 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
2,646
+7.3%
|
635
+8.8%
|
4.33
+8.3%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2,431
+6.1%
|
240
-38.9%
|
1.64
-39.3%
|
|
Feb 12, 2025
43 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
2,455
+2.9%
|
267
+6.8%
|
1.83
+7.0%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BIIB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 875045
- Former names
- BIOGEN IDEC INC. (until Mar 20, 2015); BIOGEN IDEC INC (until Apr 25, 2007); IDEC PHARMACEUTICALS CORP / DE (until Nov 12, 2003); IDEC PHARMACEUTICALS CORP / CA (until Feb 14, 1997)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.